HeartFlow shares are up +25.64% in regular trading Friday at $38.96, versus the prior close of $31.01. The move extends an after-hours surge following Q2 results: revenue rose +48% year-over-year to $64.1 million, beating forecasts, and adjusted loss per share of -$0.07 was much narrower than expected.

Waystar shares have gained approximately 8% over the last 30 days, rebounding from a mid-July dip and climbing above the $24 level following strong second-quarter results. Q2 2026 revenue reached $320 million, up 18% year-over-year, while adjusted EBITDA of $137 million exceeded Wall Street expectations.

Price target: $60 per share — representing roughly 15% upside from TXG's last close of $52.03, and aligning with the high end of recently raised analyst forecasts. Strongest bullish factor: The launch of the Atera spatial biology platform has generated extraordinary early demand, with booked orders already exceeding manufacturing capacity for 2026.

CERT closed at $7.80 on Tuesday, down -4.65% from $8.18, after an extreme intraday swing from a low of $6.33 to a high of $7.83 on heavy volume of 10.8M shares. The move followed a steep premarket gap down of nearly -19% after Q2 2026 earnings were released before the open, with the stock recovering substantially during the regular session.

WAY plunged -16.03% during regular trading on July 30, extending an after-hours drop of -5.38% that began following its Q2 2026 earnings release after the July 29 close. The selloff came despite a headline beat — EPS of $0.43 vs. $0.40 expected and revenue of $319.7M vs. $316.2M — and raised full-year 2026 guidance for both revenue and adjusted EBITDA.

TDOC plunged approximately -27.2% during the regular session on Thursday, extending a sharp after-hours selloff that began Wednesday evening following its Q2 2026 earnings release. The primary catalyst: Q2 revenue of $606.9 million missed Wall Street's $615.4 million consensus, while BetterHelp segment sales dropped -12% year-over-year amid accelerating cash-pay customer erosion.

Tempus AI shares fell approximately 28.7% over the past 30 days, dropping from $58.31 on June 29 to $41.55 on July 29, 2026. The steep decline was triggered by the announcement of a $1.5 billion all-stock acquisition of Personalis, which raised integration and dilution concerns among investors.

EVH plunged -13.64% during regular trading Thursday, dropping from a prior close of $5.57 to an intraday low near $4.81, marking its steepest single-day decline in months. Citigroup analyst Daniel Grosslight downgraded Evolent Health from Buy to Sell, citing a less favorable risk/reward after the stock rallied more than +100% over the prior three months.

TEM shares tumbled -8.94% during Monday's regular session, falling from Friday's close of $52.47 to approximately $47.78, after opening sharply lower following premarket weakness. The primary catalyst is Tempus AI's announcement that it will acquire cancer-test maker Personalis (PSNL) in an all-stock deal valued at $1.5 billion, at $16.25 per share — a transaction viewed by investors as dilutive and costly for a company still reporting net losses.

Hinge Health (HNGE) shares surged approximately 30.7% over the last 30 days, climbing from $68.35 on June 15, 2026, to $89.31 by July 14, 2026. The rally was fueled by a series of analyst price-target upgrades, bullish Q2 user-engagement data, and growing confidence in the company's AI-driven margin expansion story.

10x Genomics shares surged roughly 44% over the past 30 days, climbing from approximately $28.84 to $41.60 and repeatedly touching new 52-week highs. The rally was fueled by a series of catalysts including the acquisition of Proteintech Genomics, a multi-year research partnership with Cleveland Clinic, and a wave of analyst price target increases.

HTFL shares tumbled -14.25% during Tuesday's regular session, falling from Friday's close of $35.65 to $30.57, as heavy selling pressure continued following the June 26 disclosure of CEO John Farquhar's $1.36 million insider stock sale. The CEO sold 38,900 shares at $35.00 on June 24 under a pre-arranged Rule 10b5-1 trading plan, a move that rattled investor confidence and triggered a sharp reassessment of the company's near-term prospects.

Simulations Plus (SLP) surged approximately 29% over the last 30 days, climbing from $14.10 on May 19 to $18.24 by June 18, 2026. The definitive acquisition agreement with Altaris for $18.50 per share in cash, announced in mid-June, served as the primary catalyst for the sharp upward move.

Veeva Systems reported total revenue of $882.9 million for the fiscal 2027 first quarter ended April 30, 2026, representing 16% year-over-year growth. Subscription services revenue reached $730.2 million, up 15% from the prior year.

Veeva Systems is scheduled to report fiscal 2027 first-quarter results on June 3, 2026. The company provided revenue guidance of $855 million to $858 million for the quarter.

Tempus AI reported Q1 2026 revenue growth of 36% year-over-year to $348.1 million, driven by diagnostics and data applications. Company raised full-year 2026 revenue guidance to $1.59–$1.60 billion, targeting ~$65 million in adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization).

DOCS shares are down approximately 23% in premarket trading on May 14, 2026, following a post-earnings selloff that began after the close on May 13. Primary catalyst: Doximity issued fiscal year 2027 annual revenue guidance of $664M–$676M, falling well short of the Wall Street consensus near $697.4 million.

VEEV shares surged 10.11% to $171.75 in today's trading session from the previous close of $155.97. Primary catalyst: Announcement that VEEV will join the S&P 500 index effective May 7, replacing Coterra Energy ( CTRA ).

Shares of WAY are declining approximately 14.00% on Thursday, April 30, 2026, falling from a prior close of $25.27 to approximately $21.73 — approaching the stock's 52-week low of $21.09 set on April 10 — as Q1 2026 results released April 29 delivered a headline revenue beat that was immediately overshadowed by Q2 2026 sequential revenue guidance of flat to -1% growth, signaling that the momentum trajectory in healthcare payment software is decelerating materially.

CareCloud, Inc. (CCLD) delivers cloud-based software-as-a-service (SaaS) solutions, revenue cycle management (RCM), and electronic health records (EHR) tailored for medical practices. The company's model centers on subscription platforms that handle practice management, patient engagement, and billing, with AI-driven tools adding efficiency.